Update on chronic hepatitis C in hemophiliacs

Related Experiment Video

Updated: Oct 1, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Massimo Franchini1, Franco Capra, Annarita Tagliaferri

  • 1Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, via Delle Menegone 1, 37134 Verona, Italy. giorgio.gandini@mail.azosp.vr.it

Haematologica
|May 16, 2002
PubMed

Insights

Hepatitis C virus (HCV) infection significantly impacts patients with hereditary bleeding disorders. This review covers HCV prevalence, risk factors, and recent treatment advancements in hemophilia patients.

Area of Science:

  • Hepatology
  • Virology
  • Hematology

Background:

  • Hepatitis C virus (HCV) infection is a major health concern for individuals with hereditary bleeding disorders.
  • Historical use of non-virus inactivated clotting factor concentrates in the 1970s led to widespread HCV transmission in this population.

Purpose of the Study:

  • To review current knowledge on HCV infection in hemophilic patients.
  • To analyze the natural course of HCV infection, including prevalence, genotype distribution, and progression to severe liver disease.

Main Methods:

  • Systematic review of existing literature on HCV infection in hemophiliacs.
  • Analysis of epidemiological data, risk factors, and clinical outcomes.
  • Focus on therapeutic advancements for hepatitis C in this specific patient group.

Main Results:

  • HCV infection is highly prevalent in hemophilia populations treated before viral inactivation of clotting factors.
  • Key risk factors for progression to advanced liver disease (cirrhosis, HCC) are identified.
  • Significant progress has been made in treating hepatitis C in hemophilic patients.

Conclusions:

  • Understanding HCV natural history in hemophiliacs is crucial for managing liver disease.
  • Recent therapeutic breakthroughs offer new hope for effective HCV treatment and cure in this vulnerable group.
Abstract

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...